시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 CAR-T 치료 시장 보고서(2024년)
CAR-T Therapy Global Market Report 2024
상품코드 : 1429359
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,181,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,771,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,362,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

CAR-T 치료 시장 규모는 향후 몇 년동안 빠르게 성장할 것으로 예상됩니다. 2028년에는 16.7%의 연평균 복합 성장률(CAGR)로 47억 4,000만 달러에 달할 것으로 예상됩니다. 이러한 성장은 혈액암 발병률 증가, 의료비 증가, 강력한 의약품 파이프라인, CAR-T 치료에 대한 관심 증가에 의해 촉진될 것으로 예상됩니다. 주요 동향으로는 재설계된 CAR-T 치료제에 대한 R&D 투자, 기성품 동종 CAR-T 치료제 개발, 차세대 CAR-T 세포 제조, 최적화를 위한 AI 활용, 전략적 제휴, CAR-T 치료제 포트폴리오를 확장하기 위한 인수 등이 있습니다.

CAR-T 치료제 시장의 성장은 CAR-T 치료제 개발 및 활용을 촉진하기 위한 다양한 기관의 재정적 지원 증가에 크게 영향을 받고 있습니다. 정부 및 비정부 기관은 CAR-T 치료제 시장에서 활동하는 기업에 자금을 지원하여 연구 개발 노력을 촉진하고 급성 림프모구 백혈병(ALL) 치료를 원하는 환자를 지원하고 있습니다. 이러한 지원의 실례는 2021년 12월 캘리포니아대학교 샌디에이고 의과대학이 캘리포니아 재생의학연구소(California Institute for Regenerative Medicine, CIRM)로부터 410만 달러(한화 약 51억 원)의 대규모 보조금을 받은 것에서 확인할 수 있습니다. 이 보조금은 특히 혁신적인 키메라 항원 수용체(CAR-T) 세포 치료제의 개발을 촉진하는 것을 목표로 하고 있습니다. CAR-T 치료에 대한 다양한 기관의 지원은 시장 성장을 가속하는 원동력으로 작용할 수 있습니다.

전 세계적으로 증가하는 암 발병률은 CAR-T 치료제 시장 확대에 있어 매우 중요한 요인으로 작용하고 있습니다. 암 발생률 증가는 특정 집단이나 지역 내에서 일정 기간 동안 암 진단을 받는 환자 수가 증가한다는 것을 의미합니다. 이러한 암 발병률의 급격한 증가는 암 치료, 특히 CAR-T 치료와 같은 세포 면역 요법에 대한 대규모 연구 노력과 투자를 촉진했습니다. 이러한 치료법은 종양학 발전에 큰 진전을 가져와 암 환자의 심각한 요구를 충족시킬 수 있습니다. 예를 들어, 미국암협회(American Cancer Society)의 2021년 통계에 따르면, 같은 해 미국에서 예상되는 신규 암 환자 수와 사망자 수(신규 환자 190만 명, 사망자 60만 8,570명)는 어마어마한 수치로 예측됩니다. 따라서 암 발병률 증가는 CAR-T 치료제 시장의 성장 궤도를 주도하는 주요 동력으로 작용할 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재성 분석

제36장 부록

LSH
영문 목차

영문목차

Chimeric Antigen Receptor-T (CAR-T) therapy is a form of immunotherapy where T-cells are extracted from the patient's blood, genetically modified in a lab by adding a specialized protein receptor (CAR), enabling the T-cells to recognize and eliminate cancer cells. These modified cells are then infused back into the patient, acting as living drugs in the body.

The primary types of CAR-T therapy are monotherapy and combination therapy. Monotherapy involves treating a disease with a single drug. The targeted antigens include CD19, CD22, and others, applied in various medical conditions such as acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, among others.

The chimeric antigen receptor -T therapy market research report is one of a series of new reports from The Business Research Company that provides chimeric antigen receptor -T therapy market statistics, including chimeric antigen receptor -T therapy industry global market size, regional shares, competitors with a chimeric antigen receptor -T therapy market share, detailed chimeric antigen receptor -T therapy market segments, market trends and opportunities, and any further data you may need to thrive in the chimeric antigen receptor -T therapy industry. This chimeric antigen receptor -T therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The car-t therapy market size has grown rapidly in recent years. It will grow from $2.15 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 19.1%. The historical growth can be attributed to the rise in healthcare expenditure, increased pharmaceutical research and development (R&D) spending, and advancements in drug discovery.

The car-t therapy market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. Forecasted growth is fueled by an increase in blood cancer incidence rates, higher healthcare expenditure, a robust drug pipeline, and a heightened focus on CAR-T therapy. Key trends include R&D investments for redesigned CAR-T therapy, developing off-the-shelf allogeneic CAR-T treatment, manufacturing next-gen CAR-T cells, utilizing AI for optimization, strategic collaborations, and acquisitions to expand CAR-T therapy portfolios.

The growth of the CAR-T therapy market is significantly influenced by increased financial support from diverse organizations aimed at fostering the development and utilization of CAR-T therapy. Governmental and non-governmental bodies extend financial aid to companies operating within the CAR-T therapy market, facilitating research and development initiatives as well as aiding patients seeking treatment for acute lymphoblastic leukemia (ALL). An illustration of such support can be observed in December 2021 when the University of California San Diego School of Medicine received a substantial funding grant of US$ 4.1 million from the California Institute for Regenerative Medicine (CIRM). This grant specifically aimed at advancing the development of innovative chimeric antigen receptor (CAR-T) cell therapy. The backing provided by various organizations toward CAR-T therapy acts as a driving force propelling the market's growth.

The escalating prevalence of cancer globally stands as a pivotal factor propelling the expansion of the CAR-T therapy market. The rising incidence of cancer signifies an increased number of diagnosed cases within specific populations or regions over defined periods. This surge in cancer prevalence has spurred extensive research endeavors and investments in cancer therapies, notably cellular immunotherapies such as CAR-T therapy. These therapies mark a significant stride in oncological advancements, addressing the critical needs of cancer patients. For instance, statistics from the American Cancer Society in 2021 projected staggering figures of new cancer cases and deaths (1.9 million new cases and 608,570 deaths) anticipated in the United States that year. Hence, the mounting prevalence of cancer serves as a primary driver propelling the growth trajectory of the CAR-T therapy market.

Companies within the CAR-T therapy market are actively engaged in clinical trials aimed at assessing the efficacy of CAR-T therapy in treating multiple myeloma, a form of cancer characterized by the accumulation of cancerous cells in the bone marrow, often encroaching upon healthy blood cells. CAR-T therapy represents a potential treatment for relapsed or refractory multiple myeloma (RRMM), with CAR-T cells engineered to target the specific cells responsible for the disease. An example of this advancement can be seen in December 2021, with Novartis unveiling T-Charge, its next-generation CAR-T platform designed as a foundational framework for various new investigational CAR-T cell therapies within the Novartis pipeline. This product was in the early clinical stage (Phase I), indicating ongoing efforts to explore its potential in treating multiple myeloma.

Major companies operating in the CAR-T cell therapies market are dedicated to innovating new products such as BioCentriq to augment their profitability within the industry. BioCentriq serves as a valuable resource for organizations involved in the realm of cell and gene therapies, facilitating advancements in development, manufacturing, and research efforts, ultimately aiming to enhance patient care. For instance, in October 2023, Terumo Blood and Cell Technologies, a Japanese medical technology company, introduced BioCentriq with the objective of generating accessible public data concerning CAR-T cell manufacturing using Terumo BCT's CGT (Cell and Gene Therapy) manufacturing platforms. In collaboration with Terumo BCT, BioCentriq strives to pioneer publicly available data focusing on swift CAR-T cell manufacturing, employing the Quantum Flex and Finia platforms. This innovative trial aims to demonstrate the efficient production of high-quality CAR-T cells, leveraging the seamless integration of Terumo BCT's technology and BioCentriq's process expertise to establish streamlined, GMP-translatable workflows.

In July 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, successfully acquired Iveric Bio for $5.9 billion. This strategic move enhances Astellas' ability to address patients at high risk of vision loss due to ocular illnesses. The acquisition leverages Iveric Bio's expertise in ophthalmology alongside Astellas' global resources, aiming to create a leading organization in the field. The transaction was subject to standard closing requirements, including approval from Iveric Bio's stockholders and regulatory approvals. Iveric Bio is a U.S.-based biotech company.

Major companies operating in the car-t therapy market report are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo, Otsuka Pharmaceutical, Ono Pharmaceutical, Japan Tissue Engineering, Nipro Corporation, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune(UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Crescendo Biologics, GammaDelta Therapeutics, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Bayer AG, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio Amgen, Regen BioPharma, OncoSec Medical Incorporated, Precision BioSciences, Bellicum, Sandoz AG, GlaxoSmithKline PLC, Elekta, SudairPharma, Janssen, Aspen, Adcock Ingram

North America was the largest region in the CAR-t therapy market in 2023. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the car-t therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CAR-T Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on CAR-T therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for CAR-T therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The CAR-T therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Scope

Markets Covered:

Table of Contents

1. Executive Summary

2. CAR-T Therapy Market Characteristics

3. CAR-T Therapy Market Trends And Strategies

4. CAR-T Therapy Market - Macro Economic Scenario

5. Global CAR-T Therapy Market Size and Growth

6. CAR-T Therapy Market Segmentation

7. CAR-T Therapy Market Regional And Country Analysis

8. Asia-Pacific CAR-T Therapy Market

9. China CAR-T Therapy Market

10. India CAR-T Therapy Market

11. Japan CAR-T Therapy Market

12. Australia CAR-T Therapy Market

13. Indonesia CAR-T Therapy Market

14. South Korea CAR-T Therapy Market

15. Western Europe CAR-T Therapy Market

16. UK CAR-T Therapy Market

17. Germany CAR-T Therapy Market

18. France CAR-T Therapy Market

19. Italy CAR-T Therapy Market

20. Spain CAR-T Therapy Market

21. Eastern Europe CAR-T Therapy Market

22. Russia CAR-T Therapy Market

23. North America CAR-T Therapy Market

24. USA CAR-T Therapy Market

25. Canada CAR-T Therapy Market

26. South America CAR-T Therapy Market

27. Brazil CAR-T Therapy Market

28. Middle East CAR-T Therapy Market

29. Africa CAR-T Therapy Market

30. CAR-T Therapy Market Competitive Landscape And Company Profiles

31. CAR-T Therapy Market Other Major And Innovative Companies

32. Global CAR-T Therapy Market Competitive Benchmarking

33. Global CAR-T Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The CAR-T Therapy Market

35. CAR-T Therapy Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기